Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.50 |
| ▸ | ADK | P55263 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14364574 | 1.00 | ADORA3 (0.58) | ADORA3ADORA2AADORA1ADKCYP2C19 | |
| SCHEMBL14072684 | 1.00 | ADORA3 (0.58) | ADORA3ADORA2AADORA1ADKCYP2C19 | |
| SCHEMBL8922587 | 0.87 | ADORA3 (0.60) | ADORA3ADORA2AADORA1ADKCYP2C19 | |
| SCHEMBL10089198 | 0.87 | ADORA3 (0.60) | ADORA3ADORA2AADORA1ADKCYP2C19 | |
| SCHEMBL3427635 | 0.86 | ADORA3 (0.74) | ADORA3ADORA2AADK | |
| SCHEMBL12912354 | 0.86 | ADORA3 (0.74) | ADORA3ADORA2AADK | |
| SCHEMBL19837851 | 0.86 | ADORA3 (0.74) | ADORA3ADORA2AADK | |
| SCHEMBL13296249 | 0.86 | ADORA3 (0.74) | ADORA3ADORA2AADK | |
| SCHEMBL14264202 | 0.85 | ADORA3 (0.76) | ADORA3ADORA2AADORA1ADK | |
| SCHEMBL18172262 | 0.84 | ADORA3 (0.55) | ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989431-B2 | 4-{3-[6-Amino-9-(5-cyclopropylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-cyclohexanecarboxylic acid methyl ester; for inflammation, such as organ, tissue or cell transplantation, angioplasty (PCTA), inflammation following ischemia/reperfusion, or grafting | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-08-02 | — | — | US | disclosed |
| US-7875595-B2 | 5-[6-Amino-2-(2-hydroxy-adamantan-2-ylethynyl)-purin-9-yl]-3,4-dihydroxy-tetrahydro-furan-2-carboxylic acid cyclopropylamide for the treatment of inflammatory activity in mammalian tissue; A2A adenosine receptor agonist; autoimmune stimulation, allergic diseases, skin diseases, infectious diseases | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090298788-A1 | 2-POLYCYCLIC PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION AND ADENOSINE THERAPEUTICS, L.L.C. | 2009-12-03 | — | — | US | disclosed |
| US-7605143-B2 | 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-10-20 | — | — | US | disclosed |
| US-20090253647-A1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION AND ADENOSINE THERAPEUTICS, L.L.C. | 2009-10-08 | — | — | US | disclosed |
| US-7576069-B2 | 2-polycyclic propynyl adenosine analogs having A2A agonist activity | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-7378400-B2 | Method to reduce an inflammatory response from arthritis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-05-27 | — | — | US | disclosed |
| US-20080064653-A1 | USE OF ADENOSINE A2A MODULATORS TO TREAT SPINAL CORD INJURY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-03-13 | — | — | US | disclosed |
| US-20080027022-A1 | METHOD TO TREAT GASTRIC LESIONS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064653-A1 | USE OF ADENOSINE A2A MODULATORS TO TREAT SPINAL CORD INJURY | ADORA2A, ADORA2B, ADORA3 | ADORA3 3/4885ADORA2A 1/4885ADORA1 4/4885 |
| US-20090298788-A1 | 2-POLYCYCLIC PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA2A 1/4885ADORA1 3/4885 |
| US-20080027022-A1 | METHOD TO TREAT GASTRIC LESIONS | ADORA2A, ADORA2B, PDE4A | ADORA3 4/4885ADORA2A 1/4885ADORA1 10/4885 |
| US-20090253647-A1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA2A 1/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.